Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Study to examine if new eczema drug may prevent future development of asthma

19.11.2003


Children’s Memorial Hospital is the only Chicago site for a study to determine whether early treatment of eczema using one of a new class of anti-inflammatory drugs will prevent subsequent development of asthma and other allergic diseases. Prevalence of eczema, or atopic dermatitis, has tripled in the last few decades, in parallel with asthma. Investigators at Children’s Memorial are part of a national clinical trial involving 1,100 children, from 3 to 18 months old, to test pimecrolimus (Elidel), one of a new class of drugs called calcineurin inhibitors. Used in a cream form, pimecrolimus prevents the production of chemicals in the immune system that cause eczema symptoms, including redness, itching, cracking and bleeding.



The six-year prospective study, funded by Novartis, will be conducted in two stages. During the first three years a double blind study will compare the safety and effectiveness of pimecrolimus in conjunction with corticosteroid therapy for flare-ups, vs. corticosteroid therapy alone. Investigators hope that early treatment with pimecrolimus will reduce or prevent the need for corticosteroids. In the second three years, patients will be followed to see if they develop other allergic diseases, such as asthma, allergic rhinitis (hay fever), or allergic conjunctivitis (eye redness).

"The hope is that early and effective topical treatment of eczema in its early stages may help to prevent the later development of asthma, allergic rhinitis or allergic conjunctivitis," says Amy Paller, MD, lead site investigator and researcher at Children’s Memorial Institute for Education and Research. Paller, head of dermatology at Children’s Memorial, is professor of pediatrics and dermatology at Northwestern University’s Feinberg School of Medicine.


"While eczema develops from birth to about three years of age in most affected children, other allergies such as asthma, begin in early childhood, and hay fever begins even later," she says. "We know that 50 to 80 percent of children who have eczema in infancy or childhood go on to develop asthma or other allergic diseases later on, especially if others in their immediate family have allergic disease. But we don’t now why."

According to Paller, recent studies in mice have shown that when an allergenic substance, egg protein, was applied onto broken skin, the animals subsequently showed an allergic, asthma-like response in the lungs when exposed to the egg protein through lung inhalation. The lungs of mice whose skin had been exposed to salt water did not show an allergic response to the egg protein. This may indicate that allergenic substances that enter the bloodstream through untreated or poorly managed eczema can trigger later allergic responses, including asthma, hay fever and other conditions.

To be considered for the study, babies must have been diagnosed with eczema within the past three months, and have a parent or sibling with eczema, asthma, allergic rhinitis or allergic conjunctivitis.

Pimecrolimus has been tested for safety and effectiveness in hundreds of babies, and it is currently approved for use in eczema by the U.S. Food and Drug Administration for children as young as 2 years of age.

Children’s Memorial Institute for Education and Research is the research arm of Children’s Memorial Hospital and the center for pediatric research at Northwestern University. Children’s Memorial Hospital is the pediatric teaching hospital for Northwestern University’s Feinberg School of Medicine.

Ellen M. Hunt | EurekAlert!
Further information:
http://www.childrensmemorial.org/

More articles from Health and Medicine:

nachricht Researchers identify new way to unmask melanoma cells to the immune system
17.01.2018 | Duke University Medical Center

nachricht Study advances gene therapy for glaucoma
17.01.2018 | University of Wisconsin-Madison

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

Im Focus: A thermometer for the oceans

Measurement of noble gases in Antarctic ice cores

The oceans are the largest global heat reservoir. As a result of man-made global warming, the temperature in the global climate system increases; around 90% of...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

Polymers Based on Boron?

18.01.2018 | Life Sciences

Bioengineered soft microfibers improve T-cell production

18.01.2018 | Life Sciences

World’s oldest known oxygen oasis discovered

18.01.2018 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>